| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0038 | 1 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0024 | 1 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0024 | 1 |